Recurrence of laryngeal squamous cell carcinoma in patients undergoing organ preservation therapy: are there symptoms associated with recurrence?
Sonyara Rauedys Lisboa, Daniel Abreu Rocha, Richard Godoy Mejia, Adolfo Cotarelli Sasaki, Matheus Gerhard Rosenfeld, Leandro Luongo de Matos, Daniel Marin Ramos, Marco Aurélio Vamondes Kulcsar
Introduction: The larynx is a organ of the upper aerodigestive tract that plays an essential role in protecting the airways during swallowing. Squamous cell carcinoma is the most common malignant neoplasm affecting this region and early diagnosis has an important role in treatment outcome. Objectives: This study aims to evaluate whether patients with hypopharyngeal and/or laryngeal squamous cell carcinoma (SCC) who underwent organ preservation therapy (OPT) present at the time of relapse some factor that determines the local recurrence of the disease. Methods: Patients submitted to OPT were selected at the Cancer Institute of the State of São Paulo (ICESP), at the end of treatment, from January 2012 to December 2017. We collected retrospective data on demographics, clinical staging, location of the primary tumor, presence or absence of recurrence, weight and percentage of weight loss at different moments, alimentary pathway and symptomatology at the time of relapse. Results: The absence of symptoms was associated with the absence of relapse (p <0.001). Fully oral diet at the last visit was a significant factor for the absence of relapse (p = 0.005). The weight comparison of all the patients before the beginning of OPT and after the end of the treatment, showed an average drop of 3.4 kg. In the group-separated analysis, patients who did not recur showed an average loss of 0.7%. Patients with relapse, showed a loss of 2.0% of the weight at the time of relapse. Conclusion: Weight loss and the presence of symptoms were important predictors of recurrence with statistical significance. These factors may help to better manage these patients, with earlier investigations and, therefore, the possibility of rescue treatments with a shorter duration.
1. Bradley PJ. Symptoms and signs, staging and co-morbidity of hypopharyngeal cancer. Adv Otorhinolaryngol. 2019;83:15-26. http://dx.doi.org/10.1159/000492304. PMid:30943511.
2. Bradley P. Epidemiology of hypopharyngeal cancer. 2019. p. 1-14. http://dx.doi.org/10.1159/isbn.978-3-318-06389-9.
3. Lebo NL, Khalil D, Balram A, Holland M, Corsten M, Ted McDonald J, et al. Influence of socioeconomic status on stage at presentation of laryngeal cancer in the United States. Otolaryngol Head Neck Surg. 2019;161(5):0194599819856305. http://dx.doi.org/10.1177/0194599819856305. PMid:31184265.
4. Garneau JC, Bakst RL, Miles BA. Hypopharyngeal cancer: a state of the art review. Oral Oncol. 2018;86:244-50. http://dx.doi.org/10.1016/j.oraloncology.2018.09.025. PMid:30409307.
5. Kwon DI, Miles BA, Education Committee of the American Head and Neck Society (AHNS). Education Committee of the American Head and Neck S. Hypopharyngeal carcinoma: do you know your guidelines? Head Neck. 2019;41(3):569-76. http://dx.doi.org/10.1002/hed.24752. PMid:30570183.
6. Patel SA, Qureshi MM, Dyer MA, Jalisi S, Grillone G, Truong MT. Comparing surgical and nonsurgical larynx-preserving treatments with total laryngectomy for locally advanced laryngeal cancer. Cancer. 2019;0(0):3367-77. http://dx.doi.org/10.1002/cncr.32292. PMid:31206637.
7. Aydil U, Akmansu M, Gümüşay Ö, Eravcı FC, Bakkal FK, Yazıcı Ö, et al. Failure of concurrent chemoradiotherapy for organ preservation in laryngeal cancer: survival outcomes and recurrence patterns. Ear Nose Throat J. 2019;98(7):0145561319839788. http://dx.doi.org/10.1177/0145561319839788. PMid:30983390.
8. Eckel HE, Bradley PJ. Future Perspectives in Hypopharyngeal Cancer Care. Adv Otorhinolaryngol. 2019;83:167-75. http://dx.doi.org/10.1159/000492361. PMid:30943472.
9. Amar A, Curioni OA, Paiva DL, Rapoport A, Dedivitis RA, Cernea CR, Brandão LG. Epidemiological assessment and therapeutic response in hypopharyngeal cancer. Rev Bras Otorrinolaringol (Engl Ed). 2013;79(4):500-4. http://dx.doi.org/10.5935/1808-8694.20130089. PMid:23929153.
10. Eckel HE, Bradley PJ. Treatment options for hypopharyngeal cancer. Adv Otorhinolaryngol. 2019;83:47-53. http://dx.doi.org/10.1159/000492308. PMid:30943512.
11. Piazza C, Paderno A, Ravanelli M, Pessina C. Clinical and Radiological Evaluation of Hypopharyngeal Carcinoma. Adv Otorhinolaryngol. 2019;83:35-46. http://dx.doi.org/10.1159/000492306. PMid:30943514.
12. Brandstorp-Boesen J, Zätterström U, Evensen JF, Boysen M. Value of patientreported symptoms in the follow up of patients potentially cured of laryngeal carcinoma. J Laryngol Otol. 2019;133(6):1-7. http://dx.doi.org/10.1017/S0022215119000677. PMid:31006407.
13. Bozec A, Benezery K, Chamorey E, Ettaiche M, Vandersteen C, Dassonville O, Poissonnet G, Riss JC, Hannoun-Lévi JM, Chand ME, Leysalle A, Saada E, Sudaka A, Haudebourg J, Hebert C, Falewee MN, Demard F, Santini J, Peyrade F. Nutritional status and feeding-tube placement in patients with locally advanced hypopharyngeal cancer included in an induction chemotherapy-based larynx preservation program. Eur Arch Otorhinolaryngol. 2016;273(9):2681-7. http://dx.doi.org/10.1007/s00405-015-3785-4. PMid:26395117.